SCHEMBL9966397

SCHEMBL9966397

NC1(c2ccc(OCc3ccccc3)cc2)CCOCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.50
GAA P10253 2/20 0.50
MAOA P21397 2/20 0.50
ALOX5 P09917 2/20 0.50
MAPT P10636 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
LMNA P02545 2/20 0.47
CYP1A2 P05177 1/20 0.47
PTGS1 P23219 1/20 0.47
SLC6A2 P23975 1/20 0.47
CYP2C19 P33261 1/20 0.47
PTGS2 P35354 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HIF1A Q16665 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
MMP13 P45452 2/20 0.47
MMP1 P03956 1/20 0.47
KMT2A Q03164 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12614689 0.89 MAOB (0.58) MAOBGAAMAOAMAPTRAB9A
Hydrochloric Acid SCHEMBL28018593 0.88 MAOB (0.57) MAOBGAAMAOAMAPTRAB9A
Ammonia Solution, Strong SCHEMBL6524528 0.84 MAOB (0.51) MAOBGAAMAOAMAPTRAB9A
SCHEMBL2016642 0.82 ALOX5 (0.53) GAAALOX5MAPTLMNACYP1A2
SCHEMBL22167216 0.82 MMP2 (0.51) MAOBGAAMAOAMAPTRAB9A
SCHEMBL19615806 0.80 ALOX5 (0.75) ALOX5
SCHEMBL31582061 0.80 PARP10 (0.52) MAOBALOX5MAPTLMNACYP1A2
SCHEMBL23163539 0.79 MMP1 (0.53) MAOBGAAALOX5MAPTLMNA
SCHEMBL9966478 0.79 MAOB (0.51) MAOBGAAMAOAALOX5MAPT
SCHEMBL26038573 0.77 RORC (0.53) MAOBALOX5MAPTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171427-A1 THERAPEUTIC COMPOUNDS SANOFI (FR) 2025-05-29 US disclosed
WO-2025104230-A1 BENZOXAZOLES AS MODULATORS OF IL-17A SANOFI (FR) 2025-05-22 WO disclosed
WO-2012082817-A1 BIARYLAMIDE INHIBITORS OF LEUKOTRIENE PRODUCTION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171427-A1 THERAPEUTIC COMPOUNDS IL17A, IL2, IL36G MAOB 1748/4885GAA 199/4885MAOA 2499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.